Medicare Drug Pricing Model Affects Only Four Pharmaceutical Firms
A new Medicare payment model designed to reduce drug prices administered in doctors' offices will apply to only four pharmaceutical manufacturers. This outcome follows the industry's negotiation of most-favored-nation pricing agreements with the Trump administration, which has limited the scope of the policy impact. The Centers for Medicare & Medicaid Services (CMS) published details about this model as part of its efforts to curb healthcare costs. However, due to these negotiated deals, only a small number of firms will be affected by the new payment structure. This development highlights ongoing tensions between government cost-control measures and industry negotiations aimed at mitigating financial impacts on pharmaceutical companies.
Tickers: $LLY
Topics: Medicare most-favored-nation deals pharmaceutical pricing